Full Text View
Tabular View
No Study Results Posted
Related Studies
To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB)
This study is currently recruiting participants.
Verified by Novartis, July 2009
First Received: September 27, 2007   Last Updated: July 13, 2009   History of Changes
Sponsored by: Novartis Pharmaceuticals
Information provided by: Novartis
ClinicalTrials.gov Identifier: NCT00537537
  Purpose

This study is to evaluate the antiviral efficacy of add-on adefovir to telbivudine in non-responders to telbivudine monotherapy after 24 and 36 initial weeks. Antiviral efficacy is assessed by hepatitis B virus (HBV) DNA non-detectability (PCR <300 copies/ml) by week 104 with CHB.


Condition Intervention Phase
Hepatitis B, Chronic
Drug: Telbivudine
Phase IV

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Efficacy Study
Official Title: An Open Label, Response Adaptive Study of Telbivudine in Adults With HBeAg Positive Compensated CHB

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Antiviral efficacy with adefovir combination assessed by HBV DNA non-detectability (PCR <300 copies/ml) by week 104.

Secondary Outcome Measures:
  • Antiviral efficacy with telbivudine alone assessed by HBV DNA non-detectability (PCR <300 copies/ml) at week 24 and 36.
  • HBeAg loss & HBeAg seroconversion (defined as a loss of HBeAg and a gain of detectable level of HBeAb).
  • Alanine Transaminase (ALT) normalization, in patients with raised levels at baseline.
  • Change in HBV DNA level (log10 copies/ml) from baseline to week 4, 8, 12, 24, 36, 52, 76 and 104.
  • Viral breakthrough, defined as increase of HBV DNA by 1 log10 copies/ml from treatment nadir, at any point after week 24.

Estimated Enrollment: 100
Study Start Date: August 2007
Arms Assigned Interventions
1: Active Comparator
Telbivudine
Drug: Telbivudine
2: Active Comparator
Telbivudine
Drug: Telbivudine
3: Active Comparator
Telbivudine
Drug: Telbivudine

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

Male or female, at least 18 yrs of age; HBsAg positive, HBeAg positive and anti-HBe negative at the time of screening; Quantifiable serum HBV DNA levels of >105copies/ml; ALT levels any level; Treatment naïve; Baseline liver histology in case of ALT levels within normal limits performed within last 12 months) indicative of chronic hepatitis B changes Metavir score F >2; Willing and able to comply with the study drug regimen and all other study requirements; The patient or guardian is willing and able to explore written informed consent to participate in the study. Exclusion Criteria: Patient is pregnant or breastfeeding. Women of childbearing potential must have a negative serum beta-human chorionic gonadotropin (HCG) at Screening visit; Patient is of childbearing potential (men and women) and unwilling to use a barrier method of contraception. It is required that a barrier method of contraception be used (i.e. condom with spermicide or diaphragm with spermicide) by patients of childbearing potential (men and women) regardless of whether a hormonal agent also is used as a method of contraception; Patient is co infected with hepatitis C virus (HCV), HIV. Patients will be tested for antibodies to HCV & HIV in the Screening assessments;Patient has a medical condition that requires prolonged or frequent use of systemic acyclovir or famciclovir; Patient is currently abusing alcohol or illicit drugs, or has a history of alcohol abuse or illicit substance abuse within the preceding two years; Patient has a medical condition that requires frequent or prolonged use of systemic corticosteroids; Patients who has been on warfarin or other anticoagulants during 30 days prior to screening or if expected during the present study; Patient has any other concurrent medical condition, at clinician's discretion, likely to preclude compliance with the schedule of evaluations in the protocol, or likely to confound the efficacy or safety observations of the study Other protocol defined inclusion/exclusion criteria may apply

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00537537

Contacts
Contact: Novartis +41 61 32 41111

Locations
India
Novartis Investigative Site Recruiting
Mumbai, India
Novartis Investigative Site Recruiting
Hyderabad, India
Novartis Investigative Site Recruiting
Vellore, India
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Novartis
  More Information

No publications provided

Responsible Party: Novartis Pharmaceuticals ( External Affairs )
Study ID Numbers: CLDT600AIN01
Study First Received: September 27, 2007
Last Updated: July 13, 2009
ClinicalTrials.gov Identifier: NCT00537537     History of Changes
Health Authority: India: Drug Controller Government of India

Keywords provided by Novartis:
Hepatitis B, Chronic, Hepatitis B e Antigen positive, Adults, Telbivudine, Adefovir

Study placed in the following topic categories:
Virus Diseases
Hepatitis
Liver Diseases
Digestive System Diseases
Hepatitis, Chronic
Hepatitis B, Chronic
Hepatitis B
Hepatitis, Viral, Human
Adefovir dipivoxil
DNA Virus Infections
Adefovir
Antiviral Agents

Additional relevant MeSH terms:
Virus Diseases
Hepatitis
Liver Diseases
Digestive System Diseases
Hepatitis, Chronic
Hepatitis B, Chronic
Hepatitis B
Hepatitis, Viral, Human
DNA Virus Infections
Hepadnaviridae Infections

ClinicalTrials.gov processed this record on September 11, 2009